The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Emerging Threats in Antifungal-Resistant Fungal Pathogens
Open accessAbstract
The use of antifungal drugs in the therapy of fungal diseases can lead to the development of antifungal resistance. Resistance has been described for virtually all antifungal agents in diverse pathogens, including Candida and Aspergillus species. The majority of resistance mechanisms have also been elucidated at the molecular level in these pathogens. Drug resistance genes and genome mutations have been identified. Therapeutic choices are limited for the control of fungal diseases, and it is tempting to combine several drugs to achieve better therapeutic efficacy. In the recent years, several novel resistance patterns have been observed, including antifungal resistance originating from environmental sources in Aspergillus fumigatus and the emergence of simultaneous resistance to different antifungal classes (multidrug resistance) in different Candida species. This review will summarize these current trends.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Kontoyiannis, D. P., Marr, K. A., Park, B. J., Alexander, B. D., Anaissie, E. J., Walsh, T. J., Ito, J., Andes, D. R., Baddley, J. W., Brown, J. M., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/651263 · Cited by 1,456
Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
Pfaller, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.001 · Cited by 903
Sanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815 · cited 1×
“MDR1 is upregulated in specific strains, which results in enhanced azole efflux (45, 46).”
BackgroundSelf-citationResistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Sanglard, D., & Odds, F. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00181-0 · Cited by 784
Self-citationAlexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778
Emergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance Mechanism
Snelders, E., van der Lee, H. A. L., Kuijpers, J., Rijs, A. J. M. M., Varga, J., Samson, R. A., Mellado, E., Donders, A. R. T., Melchers, W. J. G., & Verweij, P. E. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050219 · Cited by 727
Ramage, G., Saville, S. P., Thomas, D. P., & López-Ribot, J. L. (2005) · Eukaryotic Cell · doi:10.1128/ec.4.4.633-638.2005 · Cited by 678
Amphotericin forms an extramembranous and fungicidal sterol sponge
Anderson, T. M., Clay, M. C., Cioffi, A. G., Diaz, K. A., Hisao, G. S., Tuttle, M. D., Nieuwkoop, A. J., Comellas, G., Maryum, N., Wang, S., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1496 · Cited by 528
Cited by
Synergy and antagonism in natural product extracts: when 1 + 1 does not equal 2
Caesar, L. K., & Cech, N. B. (2019) · Natural Product Reports · doi:10.1039/c9np00011a · Cited by 881
Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment
Arendrup, M. C., & Patterson, T. F. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix131 · Cited by 707
Candida auris: Epidemiology, biology, antifungal resistance, and virulence
Du, H., Bing, J., Hu, T., Ennis, C. L., Nobile, C. J., & Huang, G. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008921 · Cited by 609
Campoy, S., & Adrio, J. L. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.019 · Cited by 511
Regulation of Ergosterol Biosynthesis in Saccharomyces cerevisiae
Jordá, T., & Puig, S. (2020) · Genes · doi:10.3390/genes11070795 · Cited by 489
Anti-Fungal Efficacy and Mechanisms of Flavonoids
Al Aboody, M. S., & Mickymaray, S. (2020) · Antibiotics · doi:10.3390/antibiotics9020045 · Cited by 472
Antifungal resistance: current trends and future strategies to combat
Wiederhold, N. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s124918 · Cited by 468
Antifungal Therapy: New Advances in the Understanding and Treatment of Mycosis
Scorzoni, L., de Paula e Silva, A. C. A., Marcos, C. M., Assato, P. A., de Melo, W. C. M. A., de Oliveira, H. C., Costa-Orlandi, C. B., Mendes-Giannini, M. J. S., & Fusco-Almeida, A. M. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00036 · Cited by 418
Diagnosis of invasive fungal infections: challenges and recent developments
Fang, W., Wu, J., Cheng, M., Zhu, X., Du, M., Chen, C., Liao, W., Zhi, K., & Pan, W. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00926-2 · Cited by 356
de Oliveira Santos, G. C., Vasconcelos, C. C., Lopes, A. J. O., de Sousa Cartágenes, M. D. S., Filho, A. K. D. B., do Nascimento, F. R. F., Ramos, R. M., Pires, E. R. R. B., de Andrade, M. S., Rocha, F. M. G., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01351 · Cited by 350
Antimicrobial Metal Nanomaterials: From Passive to Stimuli‐Activated Applications
Cheeseman, S., Christofferson, A. J., Kariuki, R., Cozzolino, D., Daeneke, T., Crawford, R. J., Truong, V. K., Chapman, J., & Elbourne, A. (2020) · Advanced Science · doi:10.1002/advs.201902913 · Cited by 337
Antifungal Agents in Agriculture: Friends and Foes of Public Health
Brauer, V. S., Rezende, C. P., Pessoni, A. M., De Paula, R. G., Rangappa, K. S., Nayaka, S. C., Gupta, V. K., & Almeida, F. (2019) · Biomolecules · doi:10.3390/biom9100521 · Cited by 305
Houšť, J., Spížek, J., & Havlíček, V. (2020) · Metabolites · doi:10.3390/metabo10030106 · Cited by 254
Carolus, H., Pierson, S., Muñoz, J. F., Subotić, A., Cruz, R. B., Cuomo, C. A., & Van Dijck, P. (2021) · mBio · doi:10.1128/mbio.03333-20 · Cited by 211
Emerging Antifungal Targets and Strategies
Ivanov, M., Ćirić, A., & Stojković, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052756 · Cited by 160
“Mechanisms of antifungal resistance include decrease of effective drug concentration, drug target alterations, and metabolic bypasses [48].”
BackgroundEchinocandins in antifungal pharmacotherapy
Patil, A., & Majumdar, S. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12780 · Cited by 145
Candida albicans the main opportunistic pathogenic fungus in humans
Macias-Paz, I. U., Pérez-Hernández, S., Tavera-Tapia, A., Luna-Arias, J. P., Guerra-Cárdenas, J. E., & Reyna-Beltrán, E. (2023) · Revista Argentina de Microbiología · doi:10.1016/j.ram.2022.08.003 · Cited by 141
Fungal persister cells: The basis for recalcitrant infections?
Wuyts, J., Van Dijck, P., & Holtappels, M. (2018) · PLOS Pathogens · doi:10.1371/journal.ppat.1007301 · Cited by 136
Candida albicans gains azole resistance by altering sphingolipid composition
Gao, J., Wang, H., Li, Z., Wong, A. H.-H., Wang, Y.-Z., Guo, Y., Lin, X., Zeng, G., Liu, H., Wang, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06944-1 · Cited by 130
Molecular basis of antifungal drug resistance in yeasts
Morio, F., Jensen, R. H., Le Pape, P., & Arendrup, M. C. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.05.012 · Cited by 114
Tavakkoli, A., Johnston, T. P., & Sahebkar, A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107483 · Cited by 73
Comparative Genomics for the Elucidation of Multidrug Resistance in Candida lusitaniae
Kannan, A., Asner, S. A., Trachsel, E., Kelly, S., Parker, J., & Sanglard, D. (2019) · mBio · doi:10.1128/mbio.02512-19 · Cited by 63
Self-citationComparative Genomics of Two Sequential Candida glabrata Clinical Isolates
Vale-Silva, L., Beaudoing, E., Tran, V. D. T., & Sanglard, D. (2017) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.117.042887 · Cited by 61
“The close relationship between these two isolates reported earlier (Sanglard et al. 1999) is confirmed here due to the high level of similarity between the sequenced genomes.”
BackgroundSelf-citationKhandelwal, N. K., Chauhan, N., Sarkar, P., Esquivel, B. D., Coccetti, P., Singh, A., Coste, A. T., Gupta, M., Sanglard, D., White, T. C., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.807032 · Cited by 59
“Target alteration and the overexpression of its gene products are the most common strategies accounting for MDR phenomena in Candida species (3, 4).”
BackgroundSelf-citationGamal, A., Chu, S., McCormick, T. S., Borroto-Esoda, K., Angulo, D., & Ghannoum, M. A. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.642358 · Cited by 58
“Various mechanisms of resistance to azoles have been described in the literature including gene mutation (ERG11 mutation causing less binding), gain of function mutation (GOF), gene up-regulation (GOF in UPC2 leading to overexpression of ERG11 causing insufficient azole activity), and overexpression of efflux pumps (d…”
BackgroundChatterjee, S., & Tatu, U. (2017) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0005836 · Cited by 57
Sonderegger, C., Váradi, G., Galgóczy, L., Kocsubé, S., Posch, W., Borics, A., Dubrac, S., Tóth, G. K., Wilflingseder, D., & Marx, F. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01655 · Cited by 48
Lone, S. A., Khan, S., & Ahmad, A. (2020) · Archives of Microbiology · doi:10.1007/s00203-019-01781-2 · Cited by 32
Mahmoud, D. E., Faraag, A. H. I., & Abu El-Wafa, W. M. (2021) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-021-03158-4 · Cited by 26
“Despite the necessity of the discovery of novel antifungals, the financial resources for this field of research are still restricted and the approval process is already long and expensive (Sanglard 2016; Campoy and Adrio 2017; Wall and Lopez-Ribot 2020).”
BackgroundDumeaux, V., Massahi, S., Bettauer, V., Mottola, A., Dukovny, A., Khurdia, S. S., Costa, A. C. B. P., Omran, R. P., Simpson, S., Xie, J. L., et al. (2023) · eLife · doi:10.7554/elife.81406 · Cited by 25
Yeoh, S. F., Lee, T. J., Chew, K. L., Lin, S., Yeo, D., & Setia, S. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s165676 · Cited by 20
Gizińska, M., Staniszewska, M., & Ochal, Z. (2018) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557518666180924121209 · Cited by 15
Peng, Y., Zhang, H., Xu, M., & Tan, M.-W. (2018) · Scientific Reports · doi:10.1038/s41598-017-18868-9 · Cited by 14
McMahon, C. L., Esqueda, M., Yu, J.-J., Wall, G., Romo, J. A., Vila, T., Chaturvedi, A., Lopez-Ribot, J. L., Wormley, F., & Hung, C.-Y. (2023) · Journal of Fungi · doi:10.3390/jof9070722 · Cited by 13
“Furthermore, due to toxicity associated with amphotericin B [6] and emerging clinical resistance to azoles and echinocandins [7,8], the choice of antifungals for the treatment of invasive mycoses is further constricted.”
BackgroundEl-Houssaini, H., Elkhatib, W., Elnabawy, O., & Nasser, H. (2019) · Archives of Pharmaceutical Sciences Ain Shams University · doi:10.21608/aps.2019.20210 · Cited by 2
Metadata
- Authors
- Sanglard, D.
- Venue
- Frontiers in Medicine
- Publisher
- Frontiers Media SA
- Published
- 2016-03-15
- Volume
- 3
- Pages
- 11-11
- ISSN
- 2296-858X (ISSN-L)
- OpenAlex
- W2314322923
- Cited by
- 416
- References
- 102
- FWCI
- 47.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.